Corcept Begin Period Cash Flow vs Depreciation Analysis
CORT Stock | USD 30.17 1.04 3.33% |
Corcept Therapeutics financial indicator trend analysis is way more than just evaluating Corcept Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corcept Therapeutics is a good investment. Please check the relationship between Corcept Therapeutics Begin Period Cash Flow and its Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Begin Period Cash Flow vs Depreciation
Begin Period Cash Flow vs Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corcept Therapeutics Begin Period Cash Flow account and Depreciation. At this time, the significance of the direction appears to have weak relationship.
The correlation between Corcept Therapeutics' Begin Period Cash Flow and Depreciation is 0.38. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Depreciation in the same time period over historical financial statements of Corcept Therapeutics Incorporated, assuming nothing else is changed. The correlation between historical values of Corcept Therapeutics' Begin Period Cash Flow and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Corcept Therapeutics Incorporated are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Begin Period Cash Flow i.e., Corcept Therapeutics' Begin Period Cash Flow and Depreciation go up and down completely randomly.
Correlation Coefficient | 0.38 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Corcept Therapeutics value has been used up. For tax purposes Corcept Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Corcept Therapeutics Incorporated must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Most indicators from Corcept Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corcept Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. Selling General Administrative is likely to gain to about 193.1 M in 2024. Tax Provision is likely to gain to about 19.3 M in 2024
2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 241.5M | 289.2M | 375.1M | 393.8M | Research Development | 113.9M | 131.0M | 184.4M | 193.6M |
Corcept Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Corcept Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Corcept Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 412.3M | 571.7M | 423.8M | 583.4M | 621.5M | 652.6M | |
Other Current Liab | 30.1M | (2.1M) | (526K) | 68.5M | 654K | 621.3K | |
Total Current Liabilities | 41.1M | 10.6M | 6.9M | 81.6M | 104.5M | 109.7M | |
Accounts Payable | 7.5M | 10.6M | 6.9M | 12.0M | 17.4M | 18.3M | |
Cash | 315.3M | 476.9M | 335.8M | 436.6M | 135.6M | 116.6M | |
Other Current Assets | 6.0M | 6.7M | 10.3M | 16.4M | 27.6M | 28.9M | |
Total Liab | 41.1M | 48.4M | 48.0M | 81.6M | 114.8M | 120.6M | |
Common Stock | 120K | 122K | 127K | 131K | 133K | 85.9K | |
Property Plant Equipment | 1.1M | 1.7M | 1.0M | 1.8M | 2.0M | 2.1M | |
Total Stockholder Equity | 371.2M | 523.3M | 375.8M | 501.8M | 506.7M | 532.0M | |
Other Assets | 61.1M | 52.9M | 43.5M | 77.5M | 89.1M | 93.5M | |
Common Stock Shares Outstanding | 122.6M | 124.2M | 126.0M | 116.0M | 111.7M | 83.1M | |
Liabilities And Stockholders Equity | 412.3M | 571.7M | 423.8M | 583.4M | 621.5M | 652.6M | |
Other Stockholder Equity | 394.4M | 440.3M | 180.9M | 206.2M | 103.4M | 98.3M | |
Short Term Investments | 244.7M | 364.5M | 145.9M | 365.3M | 232.7M | 244.3M | |
Property Plant And Equipment Net | 3.4M | 2.5M | 514K | 1.1M | 315K | 559.2K | |
Net Debt | (311.9M) | (474.3M) | (335.3M) | (435.5M) | (135.4M) | (142.2M) | |
Retained Earnings | (23.6M) | 82.5M | 195.0M | 296.4M | 402.5M | 422.7M | |
Non Current Assets Total | 59.7M | 47.5M | 42.4M | 84.7M | 162.9M | 171.0M | |
Non Currrent Assets Other | 10.5M | 13.4M | 14.4M | 17.2M | 14.8M | 15.5M | |
Cash And Short Term Investments | 315.3M | 476.9M | 335.8M | 436.6M | 368.2M | 386.6M | |
Common Stock Total Equity | 117K | 120K | 122K | 127K | 146.1K | 87.7K | |
Non Current Liabilities Total | 1.9M | 37.8M | 41.0M | 9.1M | 10.3M | 12.7M | |
Property Plant And Equipment Gross | 4.5M | 4.2M | 514K | 1.1M | 315K | 299.3K | |
Total Current Assets | 352.6M | 524.2M | 381.4M | 498.7M | 458.6M | 481.6M | |
Accumulated Other Comprehensive Income | 261K | 415K | (227K) | (869K) | 609K | 639.5K | |
Net Tangible Assets | 371.2M | 523.3M | 375.8M | 501.8M | 577.1M | 606.0M | |
Retained Earnings Total Equity | (117.7M) | (23.6M) | 82.5M | 195.0M | 224.2M | 235.4M | |
Capital Surpluse | 417.2M | 457.1M | 516.1M | 591.3M | 680.1M | 426.4M | |
Inventory | 17.4M | 21.2M | 18.0M | 17.0M | 7.7M | 9.6M | |
Net Receivables | 19.9M | 26.2M | 27.6M | 45.1M | 55.1M | 57.9M | |
Net Invested Capital | 371.2M | 523.3M | 375.8M | 501.8M | 506.7M | 431.5M | |
Long Term Investments | 39.4M | 36.2M | 112.3M | 4.9M | 57.2M | 41.7M |
Pair Trading with Corcept Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corcept Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corcept Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Corcept Stock
0.86 | NPCE | Neuropace | PairCorr |
0.61 | PPERY | Bank Mandiri Persero | PairCorr |
0.58 | FNA | Paragon 28 | PairCorr |
0.58 | PPERF | Bank Mandiri Persero | PairCorr |
0.54 | BKRKY | Bank Rakyat | PairCorr |
The ability to find closely correlated positions to Corcept Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corcept Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corcept Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corcept Therapeutics Incorporated to buy it.
The correlation of Corcept Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corcept Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corcept Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corcept Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Corcept Stock analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Corcept Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corcept Therapeutics. If investors know Corcept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.786 | Earnings Share 1.04 | Revenue Per Share 5.118 | Quarterly Revenue Growth 0.39 | Return On Assets 0.1197 |
The market value of Corcept Therapeutics is measured differently than its book value, which is the value of Corcept that is recorded on the company's balance sheet. Investors also form their own opinion of Corcept Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Corcept Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corcept Therapeutics' market value can be influenced by many factors that don't directly affect Corcept Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corcept Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corcept Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corcept Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.